Protecting Patients with NERLYNX the only HER2-directed small molecule approved by the FDA ~ Oct 7th

PLEASE REGISTER ONLINE AT: PUMAREG.TSGMEDED.COM Enter Event Code:51684

This program is sponsored by Puma Biotechnology, Inc. This is not an independent educational program, and no CME credits will be provided.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:

• NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

• NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

51684 Invitation 10.7

.pdf

Download PDF • 407KB